tiprankstipranks
Advertisement
Advertisement

SLXN Stock Latest News

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
The FlySilexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
3h ago
SLXN
Silexion gains approval for SIL204 pancreatic cancer trial
PremiumCompany Announcements
Silexion gains approval for SIL204 pancreatic cancer trial
4h ago
8K
SLXN
Silexion Shareholders Reject Capital Increase and Plan Amendments
PremiumCompany Announcements
Silexion Shareholders Reject Capital Increase and Plan Amendments
20h ago
8K
SLXN
Silexion Therapeutics urges shareholders to vote ahead of EGM
PremiumThe Fly
Silexion Therapeutics urges shareholders to vote ahead of EGM
19d ago
SLXN
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN)
PremiumTipRanks Newswire
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN)
1M ago
SLXN
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
PremiumCompany AnnouncementsSilexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
2M ago
8K
SLXN
Silexion outlines 2026 plans after transformational 2025 progress
Premium
Company Announcements
Silexion outlines 2026 plans after transformational 2025 progress
3M ago
8K
SLXN
Silexion Therapeutics issues letter to shareholders
Premium
The Fly
Silexion Therapeutics issues letter to shareholders
3M ago
SLXN
Silexion Therapeutics Submits Phase 2/3 Trial Application
PremiumCompany Announcements
Silexion Therapeutics Submits Phase 2/3 Trial Application
3M ago
8K
SLXN
Silexion submits Phase 2/3 trial application to Israel for SIL204
PremiumThe Fly
Silexion submits Phase 2/3 trial application to Israel for SIL204
3M ago
SLXN
Silexion Therapeutics initiated with a Buy at Litchfield Hills
PremiumThe Fly
Silexion Therapeutics initiated with a Buy at Litchfield Hills
3M ago
SLXN
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
PremiumRatings
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
4M ago
SLXN
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial
PremiumCompany AnnouncementsSilexion Therapeutics Gains Positive Feedback for SIL204 Trial
4M ago
8K
SLXN
Silexion receives positive feedback from German Health Authority for SIL204
Premium
The Fly
Silexion receives positive feedback from German Health Authority for SIL204
4M ago
SLXN
Silexion Completes Toxicology Studies for SIL204 Therapy
Premium
Company Announcements
Silexion Completes Toxicology Studies for SIL204 Therapy
4M ago
8K
SLXN
Silexion Therapeutics completes toxicology studies for SIL204
PremiumThe Fly
Silexion Therapeutics completes toxicology studies for SIL204
4M ago
SLXN
Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year
PremiumThe Fly
Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year
4M ago
SLXN
Silexion Therapeutics files to sell 1.29M ordinary shares for holders
PremiumThe Fly
Silexion Therapeutics files to sell 1.29M ordinary shares for holders
5M ago
SLXN
Buy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal
PremiumRatings
Buy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal
6M ago
SLXN
Silexion Therapeutics Unveils Promising SIL204 Data
PremiumCompany AnnouncementsSilexion Therapeutics Unveils Promising SIL204 Data
6M ago
8K
SLXN
Silexion Therapeutics announces new data in SIL204
Premium
The Fly
Silexion Therapeutics announces new data in SIL204
6M ago
SLXN
Silexion Therapeutics files $100M mixed securities shelf
Premium
The Fly
Silexion Therapeutics files $100M mixed securities shelf
6M ago
SLXN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >